Segment and Geographical Data (Schedule of Segment Reporting Information by Business Segment) (Details) - USD ($) $ in Millions	1 Months Ended	6 Months Ended		11 Months Ended	12 Months Ended
	Dec. 29, 2023	Dec. 30, 2022	Jun. 16, 2022	Nov. 14, 2023	Dec. 31, 2021
Segment Reporting Information [Line Items]
Net sales	$ 243.0	$ 1,039.7	$ 874.6	$ 1,622.9	$ 2,208.8
Operating income (loss)	(20.2)	(316.7)	(57.8)	(517.4)	(202.9)
Intangible asset amortization	(16.2)	(318.7)	(281.8)	(449.6)	(581.1)
Restructuring and related charges, net	0.0	(11.1)	(9.6)	(0.9)	(26.9)
Other Asset Impairment Charges, Gross	(3.8)	0.0	0.0	(179.9)	(154.9)
Other Asset Impairment Charges	2.6	0.0	0.0	135.9	154.9
Opioid-Related Litigation Settlement loss	0.0	0.0	0.0	0.0	125.0
Depreciation and amortization	25.8	347.5	321.8	490.3	675.8
Restructuring and related costs, accelerated depreciation	0.0	1.0	0.0	0.8	2.1
Employee Benefits and Share-based Compensation	0.0	(1.4)	(1.7)	(8.9)	(10.2)
Assets	3,733.6	6,013.8
Inventory provisions				44.0
StrataGraft [Member]
Segment Reporting Information [Line Items]
Other Asset Impairment Charges, Gross	3.8
Petition Amount Filed with Bankruptcy Court
Segment Reporting Information [Line Items]
Bad Debt Expense, Customer Bankruptcy, Pre-Petition Amount	0.0	(6.4)	0.0	0.0	0.0
Specialty Brands [Member]
Segment Reporting Information [Line Items]
Other Asset Impairment Charges					154.9
Specialty Brands [Member] | StrataGraft [Member]
Segment Reporting Information [Line Items]
Other Asset Impairment Charges				50.1
Specialty Generics [Member]
Segment Reporting Information [Line Items]
Other Asset Impairment Charges				85.8
Operating Segments
Segment Reporting Information [Line Items]
Operating income (loss)	14.8	110.2	332.5	366.1	920.7
Operating Segments | Specialty Brands [Member]
Segment Reporting Information [Line Items]
Net sales	139.8	682.4	587.1	949.2	1,547.0
Operating income (loss)	9.0	113.8	267.2	209.9	812.8
Depreciation and amortization	15.3	323.6	288.4	455.3	597.7
Operating Segments | Specialty Generics [Member]
Segment Reporting Information [Line Items]
Net sales	103.2	357.3	287.5	673.7	661.8
Operating income (loss)	5.8	(3.6)	65.3	156.2	107.9
Depreciation and amortization	10.5	23.9	33.4	35.0	78.1
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Corporate and allocated expenses	(4.0)	(39.3)	(48.2)	(45.8)	(129.6)	[1]
Intangible asset amortization	(25.8)	(347.5)	(321.8)	(490.3)	(675.8)
Separation costs	1.4	21.2	9.0	157.7	1.2	[2]
Opioid-Related Litigation Settlement loss	$ 0.0	$ 0.0	$ 0.0	$ 0.0	$ (125.0)

[1] Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments. (3)Includes $135.9 million and $154.9 million of impairment charges on intangible assets during the period December 31, 2022 through November 14, 2023 (Predecessor) and fiscal 2021 (Predecessor), respectively, as further described in Note 12, a $44.0 million Acthar Gel inventory write-down to net realizable value during the period December 31, 2022 through November 14, 2023 (Predecessor), and $3.8 million of impairment charges on StrataGraft long-lived assets during the period November 15, 2023 through December 29, 2023 (Successor).

[2] Represents costs primarily related to professional fees incurred by the Company (including where the Company is responsible for the fees of third parties) in connection with its evaluation of its financial situation and related discussions with its stakeholders prior to the commencement of the 2023 Bankruptcy Proceedings, expenses incurred related to the severance of certain former executives of the Predecessor as a result of the 2020 Bankruptcy Proceedings, in addition to professional fees and costs incurred as the Company explores potential sales of non-core assets to enable further deleveraging post-emergence. As of the 2023 Petition Date and 2020 Petition Date, professional fees directly related to the 2023 Bankruptcy Proceedings and 2020 Bankruptcy Proceedings, respectively, that were previously reflected as liabilities management and separation costs were classified on a go-forward basis as reorganization items, net until the 2023 Effective Date and the 2020 Effective Date, respectively.